
Walker Chandio & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Rossari Biotech Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended **30 June 2025**, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Rossari Biotech Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of four subsidiaries included in the Statement, whose financial results reflects total revenues of ₹ 3,629.10 million, total net profit after tax of ₹ 115.84 million, total comprehensive income of ₹ 114.22 million for the quarter ended on 30 June 2025, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 4.57 million and total comprehensive income of ₹ 4.57 million for the quarter ended on 30 June 2025, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of these matters with respect to our reliance on the work done by and the reports of the other auditors.

6. The Statement includes the Interim financial information of five subsidiaries, which have not been reviewed by their auditors, whose interim financial information reflects total revenues of ₹ 2.98 million, net loss after tax of ₹ (10.75) million, total comprehensive loss of ₹ (9.49) million for the quarter ended 30 June 2025, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.64 million and total comprehensive income of ₹ 0.64 million for the quarter ended on 30 June 2025, in respect of a joint venture, based on their interim financial information, which have not been reviewed by their auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a joint venture, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Bharat Shetty

Partner

Membership No. 106815

UDIN: 25106815BMJIGL3556

Place: Mumbai

Date: 19 July 2025

Rossari Biotech Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of
the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

Sr. No.	Particulars
	Subsidiaries
1	Buzil Rossari Private Limited
2	Rossari Consumer Products Private Limited
3	Unitop Chemicals Private Limited
4	Tristar Intermediates Private Limited
5	Rossari Bangladesh Limited
6	Rossari Global DMCC
7	Rossari International Company Limited
	Step down subsidiaries
1	Rossari Biotech Trading FZE
2	Unistar Thai Co. Ltd
	Joint Venture
1	Hextar Unitop SDN BHD (Joint venture of Unitop Chemicals Private Limited)
	Associate
1	Romakk Chemicals Private Limited



ROSSARI BIOTECH LIMITED
(AN ISO9001:2005 & 14001:2015 Certified Company)




Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

Particulars	Quarter ended			Rs. in million
	30th June, 2025	31st March, 2025	30th June, 2024	Year Ended 31st March, 2025
	Unaudited	Refer note 5	Unaudited	Audited
I INCOME				
Revenue from operations	5,437.16	5,795.62	4,896.50	20,802.94
Other Income	12.00	17.91	9.48	40.09
Total Income	5,449.16	5,813.53	4,905.98	20,843.03
II EXPENSES				
Cost of materials consumed	3,343.99	3,697.71	2,840.34	12,996.44
Purchase of stock-in-trade	289.57	338.84	425.53	1,647.68
Changes in inventories of finished goods, work-in-progress and stock-in-trade	79.92	(20.07)	143.14	(311.15)
Employee benefits expense	374.65	354.89	285.84	1,323.30
Finance costs	57.28	55.02	36.85	178.11
Depreciation and amortisation expenses	177.49	182.19	153.72	670.73
Other expenses	670.48	729.34	552.79	2,495.85
Total Expenses	4,993.38	5,337.92	4,438.21	19,000.96
III Profit before share of profit of joint venture, associate, exceptional items and tax [I-II]	455.78	475.61	467.77	1,842.07
IV Share of profit of joint venture and associate	5.21	1.45	2.10	9.78
V Profit before exceptional items and tax [III+IV]	460.99	477.06	469.87	1,851.85
VI Exceptional items	-	-	-	-
VII Profit before tax [V-VI]	460.99	477.06	469.87	1,851.85
VIII Tax Expense				
Current tax charge	161.05	144.19	152.57	590.71
Deferred tax (credit)	(36.02)	(11.57)	(31.69)	(102.64)
Total Tax Expense	125.03	132.62	120.88	488.07
IX Profit after tax [VII-VIII]	335.96	344.44	348.99	1,363.78
X Other comprehensive income / (loss)				
A Items that will not be reclassified to profit or loss				
i Remeasurements of the defined benefit plans	(3.10)	(13.98)	0.03	(12.67)
ii Income tax relating to items that will not be reclassified to profit or loss	0.78	3.51	(0.01)	3.18
B Items that will be reclassified subsequently to profit or loss				
i Exchange difference on translation of foreign operations	1.26	(0.76)	-	(0.76)
Total other comprehensive income/(loss)	(1.06)	(11.23)	0.02	(10.25)
XI Total comprehensive income (IX + X)	334.90	333.21	349.01	1,353.53
Profit for the period/year attributable to				
Owners of the Company	335.96	344.44	348.99	1,363.78
Non Controlling Interest	-	-	-	-
	335.96	344.44	348.99	1,363.78
Other Comprehensive Income/(Loss) attributable to				
Owners of the Company	(1.06)	(11.23)	0.02	(10.25)
Non Controlling Interest	-	-	-	-
	(1.06)	(11.23)	0.02	(10.25)
Total Comprehensive Income attributable to				
Owners of the Company	334.90	333.21	349.01	1,353.53
Non Controlling Interest	-	-	-	-
	334.90	333.21	349.01	1,353.53
Paid up equity share capital (Face value of Rs 2.00 per share)	110.73	110.73	110.49	110.73
Other equity				11,743.76
Earnings per equity share (in Rs.)				
Basic	6.07*	6.22*	6.32*	24.66
Diluted	6.06*	6.21*	6.30*	24.63

*Not annualized



(Handwritten signature)

Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 19th July, 2025.
2. The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The consolidated financial results include the financial results of three foreign subsidiaries - Rossari Global DMCC, Rossari Bangladesh Limited, Rossari International Company Limited, two step-down foreign subsidiaries - Rossari Biotech Trading FZE and Unistar Thai Co. Ltd., (100% subsidiary of Rossari Global DMCC), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. (a joint venture company of Unitop Chemicals Private Limited).
4. The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.
5. The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
6. During the quarter ended 30th June, 2025, the Parent Company has allotted 2,825 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
7. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, which are not material.

For ROSSARI BIOTECH LIMITED



EDWARD MENEZES
Executive Chairman
DIN:00149205

Place : Mumbai
Date : 19th July, 2025

Walker ChandioK & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Rossari Biotech Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Rossari Biotech Limited** ('the Company') for the quarter ended **30 June 2025**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Rossari Biotech Limited

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandlok & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Bharat Shetty

Partner

Membership No. 106815

UDIN: 25106815BMJIGK3896

Place: Mumbai

Date: 19 July 2025

ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)

Regd. Office : Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (W) Mumbai – 400079

T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818



STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

Particulars	Quarter ended			Rs. In million
	30th June, 2025	31st March, 2025	30th June, 2024	31st March, 2025
	Unaudited	Refer Note 4	Unaudited	Audited
I INCOME				
Revenue from operations	3,657.58	4,266.53	3,007.08	14,316.28
Other Income	17.42	23.96	12.59	57.42
Total Income	3,675.00	4,290.49	3,019.67	14,373.70
II EXPENSES				
Cost of materials consumed	2,117.43	2,586.72	1,299.80	8,111.17
Purchase of stock-in-trade	500.84	618.21	840.36	2,530.00
Changes in inventory of finished goods, work-in-progress and stock-in-trade	93.40	(46.77)	44.54	(170.42)
Employee benefit expenses	156.66	157.62	143.21	600.11
Finance costs	30.93	30.75	23.28	95.84
Depreciation and amortisation expenses	71.50	76.63	60.63	276.90
Other expenses	349.80	428.75	281.13	1,383.07
Total Expenses	3,320.56	3,851.91	2,692.95	12,826.67
III Profit before exceptional items and tax [I-II]	354.44	438.58	326.72	1,547.03
IV Exceptional items	-	-	-	-
V Profit before tax [III-IV]	354.44	438.58	326.72	1,547.03
VI Tax Expense				
Current tax charge	96.42	123.51	85.25	421.86
Deferred tax charge/(credit)	(4.31)	(8.57)	(1.81)	(22.25)
Total Tax Expense	92.11	114.94	83.44	399.61
VII Profit after tax [V-VI]	262.33	323.64	243.28	1,147.42
VIII Other comprehensive income / (loss)				
A Items that will not be reclassified to profit or loss				
i Remeasurements of the defined benefit plans	(0.94)	(3.63)	(0.04)	(3.75)
ii Income tax relating to items that will not be reclassified to profit or loss	0.24	0.91	0.01	0.94
B Items that will be reclassified subsequently to profit or loss	-	-	-	-
Total other comprehensive income/(loss)	(0.70)	(2.72)	(0.03)	(2.81)
IX Total comprehensive income (VII + VIII)	261.63	320.92	243.25	1,144.61
Paid up equity share capital (Face value of Rs 2 per share)	110.73	110.73	110.49	110.73
Other equity				10,661.01
X Earnings per equity share (in Rs.)				
Basic	4.74*	5.85*	4.40*	20.75
Diluted	4.73*	5.84*	4.40*	20.72

*Not annualized



Notes:

1. The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 19th July, 2025.
2. The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.
4. The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
5. During the quarter ended 30th June, 2025, the Company has allotted 2,825 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.
6. Previous year / period figures have been regrouped to make them comparable with the current year / period figures, which are not material.



For ROSSARI BIOTECH LIMITED


EDWARD MENEZES
Executive Chairman
DIN:00149205

Place : Mumbai
Date : 19th July, 2025

